Abstract
Experiments in different animal species have shown that febrile conditions, induced by Escherichia coli lipopolysaccharide (LPS), may alter the pharmacokinetic properties of drugs. The objective was to study the effects of a LPS-induced acute-phase response (APR) model on plasma pharmacokinetics of florfenicol (FFC) after its intravenous administration in sheep. Six adult clinically healthy Suffolk Down sheep, 8months old and 35.5±2.2kg in body weight (bw), were distributed through a crossover factorial 2×2 design, with 4weeks of washout. Pairs of sheep similar in body weight were assigned to experimental groups: Group 1 (LPS) was treated with three intravenous doses of 1μg/kg bw of E.coli LPS before FFC treatment. Group 2 (control) was treated with an equivalent volume of saline solution (SS) at similar intervals as LPS. At 24h after the first injection of LPS or SS, an intravenous bolus of 20mg/kg bw of FFC was administered. Blood samples (5mL) were collected before drug administration and at different times between 0.05 and 48.0h after treatment. FFC plasma concentrations were determined by liquid chromatography. A noncompartmental pharmacokinetic model was used for data analysis, and data were compared using a Mann-Whitney U-test. The mean values of AUC0-∞ in the endotoxaemic sheep (105.9±14.3μg·h/mL) were significantly higher (P<0.05) than values observed in healthy sheep (78.4±5.2μg·h/mL). The total mean plasma clearance (CLT ) decreased from 257.7±16.9mL·h/kg in the control group to 198.2±24.1 mL·h/kg in LPS-treated sheep. A significant increase (P<0.05) in the terminal half-life was observed in the endotoxaemic sheep (16.9±3.8h) compared to the values observed in healthy sheep (10.4±3.2h). In conclusion, the APR induced by the intravenous administration of E.coli LPS in sheep produces higher plasma concentrations of FFC due to a decrease in the total body clearance of the drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of veterinary pharmacology and therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.